Adbry shows long-term efficacy in atopic dermatitis

Key takeaways:

• Full results of the long-term ECZTEND trial of Adbry for atopic dermatitis were announced at the Fall Clinical Dermatology Conference.
• Of 1,672 patients, 92.9% achieved a reduction of at least 75% in EASI score.

LEO Pharma presented full results from its long-term trial of Adbry for atopic dermatitis at the Fall Clinical Dermatology Conference, according to a company press release.

The phase 3, long-term, 5-year, open-label, single-arm ECZTEND extension trial included 1,672 patients aged 12 years and older who previously participated in one of the nine ECZTRA trials and evaluated the safety and efficacy of Adbry (tralokinumab-ldrm, LEO Pharma).

In 92.9% of patients, a reduction of at least 75% in EASI score was found from baseline to week 248, with 66.7% achieved an IGA score of 0 or 1.

“With the release of the final results from the ECZTEND open-label extension study, we are pleased to present robust evidence further supporting the long-term safety and efficacy of tralokinumab-ldrm in the treatment of moderate to severe atopic dermatitis,” Brian Hilberdink, executive vice president and president, region North America, LEO Pharma, said in the release.

Patients also experienced significant improvements in itch, sleep and quality of life.

“These long-term findings are crucial for clinical practice, providing health care professionals with the data needed to prescribe tralokinumab-ldrm for sustained use confidently,” Andrew Blauvelt, MD, MBA, founder of Blauvelt Consulting and international coordinating investigator of the ECZTEND trial, said in the release. “Ultimately, these comprehensive results will help improve their ability to manage this debilitating condition and enhance patient care.”